ReviewNature methods2008
Engineering GPCR signaling pathways with RASSLs.
Review in Nature methods, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 253 citations in OpenAlex.
- Off-target effects of DREADD ligands revealed by an anesthesia emergence paradigm in mice.Cell reports methods · 2026Article
- Activity-restoring mutations in the histamine HProtein science : a publication of the Protein Society · 2026Article
- Molecular Tools to Study and Control Dopaminergic Neurotransmission With Light.Medicinal research reviews · 2025Review
- Advancements in DNA-Driven Precision Modulation of Cell Surface Receptor for Programmable Cellular Functions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Co-release of opposing signaling molecules controls the escalation and release of aggression.bioRxiv : the preprint server for biology · 2025Article
- Principles and Design of Molecular Tools for Sensing and Perturbing Cell Surface Receptor Activity.Chemical reviews · 2025Review
- Neuromodulator and neuropeptide sensors and probes for precise circuit interrogation in vivo.Science (New York, N.Y.) · 2024Review
- BEAM: A combinatorial recombinase toolbox for binary gene expression and mosaic genetic analysis.Cell reports · 2024Article
- Updated Toolbox for Assessing Neuronal Network Reconstruction after Cell Therapy.Bioengineering (Basel, Switzerland) · 2024Review
- Capillary malformations.The Journal of clinical investigation · 2024Review
- The proarrhythmogenic role of autonomics and emerging neuromodulation approaches to prevent sudden death in cardiac ion channelopathies.Cardiovascular research · 2024Review
- Programmable synthetic receptors: the next-generation of cell and gene therapies.Signal transduction and targeted therapy · 2024Review
- Engineered Artificial Human Neutrophils Exhibit Mature Functional Performance.ACS synthetic biology · 2023Article
- Applications of synthetic biology in medical and pharmaceutical fields.Signal transduction and targeted therapy · 2023Review
- MEK inhibition reduced vascular tumor growth and coagulopathy in a mouse model with hyperactive GNAQ.Nature communications · 2023Article
- Computational structural-based GPCR optimization for user-defined ligand: Implications for the development of biosensors.Computational and structural biotechnology journal · 2023Article
- High-performance optical control of GPCR signaling by bistable animal opsins MosOpn3 and LamPP in a molecular property-dependent manner.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Parameterized Computational Framework for the Description and Design of Genetic Circuits of Morphogenesis Based on Contact-Dependent Signaling and Changes in Cell-Cell Adhesion.ACS synthetic biology · 2022Article
- Chemogenetics of cell surface receptors: beyond genetic and pharmacological approaches.RSC chemical biology · 2022Review
- Chemogenetics as a neuromodulatory approach to treating neuropsychiatric diseases and disorders.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
Abstract
We are creating families of designer G protein-coupled receptors (GPCRs) to allow for precise spatiotemporal control of GPCR signaling in vivo. These engineered GPCRs, called receptors activated solely by synthetic ligands (RASSLs), are unresponsive to endogenous ligands but can be activated by nanomolar concentrations of pharmacologically inert, drug-like small molecules. Currently, RASSLs exist for the three major GPCR signaling pathways (G(s), G(i) and G(q)). We review these advances here to facilitate the use of these powerful and diverse tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.